2 results
Approved WMOPending
Assess the neurological efficacy of ambroxol in adults and children with GD3.
Approved WMORecruiting
Primary objective: To evaluate the comparative long-term safety of TAK-503 treatment (formerly known as SPD503) in children and adolescentsaged 6 to 17 years diagnosed with ADHD for whom stimulants are not suitable, not tolerated, or shown to…